PL2467489T3 - Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych - Google Patents

Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych

Info

Publication number
PL2467489T3
PL2467489T3 PL10743083T PL10743083T PL2467489T3 PL 2467489 T3 PL2467489 T3 PL 2467489T3 PL 10743083 T PL10743083 T PL 10743083T PL 10743083 T PL10743083 T PL 10743083T PL 2467489 T3 PL2467489 T3 PL 2467489T3
Authority
PL
Poland
Prior art keywords
baculovirus
based production
biopharmaceuticals
free
baculoviral virions
Prior art date
Application number
PL10743083T
Other languages
English (en)
Inventor
Otto-Wilhelm Merten
Martin Marek
Oers Monique Van
Original Assignee
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genethon filed Critical Genethon
Publication of PL2467489T3 publication Critical patent/PL2467489T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14151Methods of production or purification of viral material
    • C12N2710/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/50Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL10743083T 2009-08-17 2010-08-05 Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych PL2467489T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305761A EP2292781A1 (en) 2009-08-17 2009-08-17 Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
EP10743083.7A EP2467489B1 (en) 2009-08-17 2010-08-05 Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
PCT/EP2010/061456 WO2011020710A2 (en) 2009-08-17 2010-08-05 Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions

Publications (1)

Publication Number Publication Date
PL2467489T3 true PL2467489T3 (pl) 2015-10-30

Family

ID=41203903

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16205440T PL3187589T3 (pl) 2009-08-17 2010-08-05 Oparte na bakulowirusie wytwarzanie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych
PL10743083T PL2467489T3 (pl) 2009-08-17 2010-08-05 Wytwarzanie opartych na bakulowirusie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16205440T PL3187589T3 (pl) 2009-08-17 2010-08-05 Oparte na bakulowirusie wytwarzanie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych

Country Status (10)

Country Link
US (4) US8993317B2 (pl)
EP (4) EP2292781A1 (pl)
CN (1) CN102686732A (pl)
CA (2) CA2771250C (pl)
DK (3) DK2933336T3 (pl)
ES (3) ES2787706T3 (pl)
HU (1) HUE025056T2 (pl)
PL (2) PL3187589T3 (pl)
PT (3) PT2933336T (pl)
WO (1) WO2011020710A2 (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292781A1 (en) * 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
FR2978456B1 (fr) 2011-07-27 2015-02-20 Genethon Systeme baculoviral pour l'expression d'un vecteur de therapie genique
US20140287460A1 (en) * 2011-07-27 2014-09-25 Gbiotech Sarl Production of recombinant protein in insect cells using a baculovirus expression system
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
RU2619161C2 (ru) * 2012-06-12 2017-05-12 Альтернативе Гене Экспрессион С.Л. Элементы рекомбинантной днк для экспрессии рекомбинантных белков в клетке-хозяине
CN106414474B (zh) 2014-03-17 2021-01-15 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
BR112017018846A2 (pt) 2015-03-02 2018-07-31 Adverum Biotechnologies, Inc. composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
JP7064214B2 (ja) 2015-09-28 2022-05-10 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗体回避性ウイルスベクターのための方法および組成物
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102652994B1 (ko) 2016-05-18 2024-04-01 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
JP7220080B2 (ja) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド ハンチントン病治療組成物及び方法
EP3464596B1 (en) * 2016-06-07 2025-07-30 Cepheid Thermostable polymerase inhibitor compositions and methods
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
AU2018261790B2 (en) 2017-05-05 2024-10-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
KR102850887B1 (ko) 2017-08-03 2025-08-28 보이저 테라퓨틱스, 인크. Aav의 전달을 위한 조성물 및 방법
TWI904068B (zh) 2017-08-09 2025-11-11 美商生物化學醫療公司 核酸分子及其用途
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP4454654A3 (en) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP3773743A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
WO2019237374A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Mtabc3基因定点整合至a375细胞的方法及其应用
WO2019237376A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 TXGP1基因定点整合至Raji细胞的方法及其应用
WO2019237377A1 (zh) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 一种将SLEB2基因定点整合至Jurkat细胞的方法及其应用
CN108823176B (zh) * 2018-07-20 2021-09-28 山西大学 一种重组杆状病毒及其构建方法和应用
CA3108799A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
CN108998455B (zh) * 2018-08-13 2021-03-16 西南大学 家蚕核型多角体病毒诱导型39k启动子及其重组载体和应用
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
CN111434774B (zh) * 2019-01-11 2023-06-23 陕西杆粒生物科技有限公司 一种解除高滴度抑制的杆状病毒表达载体
CA3133453A1 (en) 2019-03-21 2020-09-24 Daniel Mccoy Recombinant adeno-associated virus vectors
EP3947700A4 (en) 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
WO2020264139A1 (en) * 2019-06-26 2020-12-30 Virovek, Inc. Baculovirus expression system
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
CN110940807A (zh) * 2019-11-08 2020-03-31 江苏科技大学 研究家蚕基因抑制BmNPV DNA复制相关基因的表达的方法
KR20230068444A (ko) 2020-08-19 2023-05-17 사렙타 쎄러퓨틱스 인코퍼레이티드 레트 증후군의 치료를 위한 아데노 관련 바이러스 벡터
WO2022046665A1 (en) * 2020-08-23 2022-03-03 Bioverativ Therapeutics Inc. MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
CN115491377B (zh) * 2021-06-18 2025-09-16 北京三诺佳邑生物技术有限责任公司 一种诱导rna干扰和降低并清除细胞中病毒污染的核苷酸序列及应用
CN115491436A (zh) * 2021-06-18 2022-12-20 舒泰神(北京)生物制药股份有限公司 一种用于检测杆状病毒残留dna的引物、探针及方法
JP2024534123A (ja) * 2021-08-23 2024-09-18 バイオベラティブ セラピューティクス インコーポレイテッド バキュロウイルス発現システム
CN114058598B (zh) * 2021-11-04 2023-04-28 中国科学院精密测量科学与技术创新研究院 新的重组杆状病毒基因组插入位点及其应用
TW202404993A (zh) 2022-04-11 2024-02-01 美商特納亞治療股份有限公司 具經工程化蛋白殼之腺相關病毒
CN118086400B (zh) * 2024-04-17 2024-07-19 和元生物技术(上海)股份有限公司 核酸分子、包含其的重组杆状病毒及其应用
CN120137918B (zh) * 2025-05-12 2025-09-02 中国林业科学研究院高原林业研究所 重组dsRNA-杆状病毒及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
ATE78293T1 (de) 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
DK518384A (da) 1984-01-31 1985-07-01 Idaho Res Found Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse
CN1062601C (zh) * 1992-03-24 2001-02-28 剑桥药物研究有限公司 病毒疫苗
FR2756297B1 (fr) * 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
GB9919409D0 (en) * 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
EP1543128A4 (en) * 2002-07-18 2008-02-20 Invitrogen Corp VIRUS VECTORS WITH RECOMBINATION SITES
WO2005072364A2 (en) * 2004-01-27 2005-08-11 University Of Florida A modified baculovirus expression system for production of pseudotyped raav vector
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions

Also Published As

Publication number Publication date
DK3187589T3 (da) 2020-04-14
EP3187589B1 (en) 2020-02-12
US11236307B2 (en) 2022-02-01
DK2467489T3 (en) 2015-07-20
ES2542740T3 (es) 2015-08-11
EP2467489A2 (en) 2012-06-27
WO2011020710A3 (en) 2011-05-05
ES2627744T3 (es) 2017-07-31
EP3187589A3 (en) 2017-09-20
US20120149010A1 (en) 2012-06-14
EP3187589A2 (en) 2017-07-05
EP2467489B1 (en) 2015-05-27
EP2933336A3 (en) 2015-12-02
US20200002683A1 (en) 2020-01-02
PL3187589T3 (pl) 2020-06-29
US20180127728A1 (en) 2018-05-10
EP2292781A1 (en) 2011-03-09
HUE025056T2 (en) 2016-01-28
WO2011020710A2 (en) 2011-02-24
PT2467489E (pt) 2015-09-04
US8993317B2 (en) 2015-03-31
US9862934B2 (en) 2018-01-09
CA2771250C (en) 2019-09-17
CA3050271A1 (en) 2011-02-24
PT2933336T (pt) 2017-06-12
US10428315B2 (en) 2019-10-01
CN102686732A (zh) 2012-09-19
DK2933336T3 (en) 2017-06-12
EP2933336B1 (en) 2017-03-29
PT3187589T (pt) 2020-05-07
ES2787706T3 (es) 2020-10-16
EP2933336A2 (en) 2015-10-21
CA2771250A1 (en) 2011-02-24
US20150252335A1 (en) 2015-09-10

Similar Documents

Publication Publication Date Title
PL3187589T3 (pl) Oparte na bakulowirusie wytwarzanie środków biofarmaceutycznych wolnych od zanieczyszczających wirionów bakulowirusowych
PL2289864T3 (pl) Proces otrzymywania związków fluorowych
SI2496562T1 (sl) Postopek priprave kalkobutrola
PL2604268T3 (pl) Sposób wytwarzania pochodnych tiazolu
PT2913337T (pt) Processo para a produção de sofosbuvir
IL220170A0 (en) New process for the preparation of dronedarone
IL216322A0 (en) Process for the production of dronedarone intermediates
IL216942A0 (en) Process for the manufacture of alkenones
IL214906A (en) A process for making Iwan
ZA201105709B (en) Process for the synthesis of cleistanthin
EP2397438A4 (en) METHOD FOR PRODUCING A FLUOR COMPOUND
EP2464584A4 (en) SHIPPING OF LIQUIDS
IL219111A0 (en) Process for the manufacture of organic compounds
ZA201107259B (en) Process for the synthesis of a propargylic alcohol
IL217139A0 (en) Process for the preparation of arylpyridinyl compounds
ZA201106175B (en) Chemical process for the production of haloalkenone ethers
EP2423212A4 (en) PROCESS FOR PREPARING A 2-AZAADAMANTAN COMPOUND FROM A BICYCLOCARBAMATE COMPOUND
EP2393786A4 (en) NEW POLYMORPHIC FROM LOPINAVIR
IL215022A0 (en) Novel process for the preparation of enaminocarbonyl compounds
FI20095142L (fi) Laitteisto lasimateriaalin valmistamiseksi
IL217460A0 (en) Novel process for the preparation of 4-aminobut-2-enolides
IL217402A0 (en) Continuous flow process for the preparation of sulphoxide compounds
GB0905895D0 (en) Process for the preparation of chalcogenone compounds
SI2387557T1 (sl) Postopek za pripravo N-(5-(3-dimetilamino-akriloil)-2-fluorofenil)-N-metil-acetamida
GB0915850D0 (en) Inspection of glazing components